|
15 May 2020 |
BioInvent and Transgene present preclinical data demonstrating BT-001’s powerful activity against solid tumors
|
|
14 May 2020 |
Solid Biosciences Presents Data from Duchenne Muscular Dystrophy Gene Therapy Program at ASGCT 23rd Annual Meeting
|
|
14 May 2020 |
Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital Ichthyosis (ARCI)
|
|
14 May 2020 |
AVROBIO Presents New Preclinical Data on Lentiviral Gene Therapy Program for Pompe Disease at ASGCT 2020
|
|
14 May 2020 |
Novadip Biosciences Reports Positive Interim Analysis of Phase I/II Bone Non-Union Study with NVD003
|
|
14 May 2020 |
American Society of Clinical Oncology (ASCO) Abstract Reports Initial ALLO-501 ALPHA Phase 1 Data in Relapsed/Refractory Non-Hodgkin Lymphoma
|
|
14 May 2020 |
Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002
|
|
14 May 2020 |
Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy
|
|
14 May 2020 |
Janssen's BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
|
|
13 May 2020 |
FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy
|
|
13 May 2020 |
Stoke Therapeutics Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited Optic Nerve Disorder
|
|
13 May 2020 |
Legend Biotech and Noile-Immune Biotech Announce Collaborative Research and Licensing Agreement
|
|
13 May 2020 |
AVROBIO Reports Updated Clinical Data from Investigational Gene Therapy Programs for Fabry Disease and Cystinosis
|
|
13 May 2020 |
Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma
|
|
13 May 2020 |
Genocea Introduces GEN-011, a Transformational T cell Therapy Designed to Improve on Current Limitations of TIL Therapy
|
|
13 May 2020 |
Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies
|
|
12 May 2020 |
Dyno Therapeutics Announces Ocular Collaboration with Novartis to Develop Improved Gene Therapies with AAV Vectors based on AI Technology
|
|
12 May 2020 |
bluebird bio Announces Amended BCMA CAR-T Collaboration Agreement
|
|
10 May 2020 |
jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Global Ophthalmology Leader Santen Pharmaceutical
|
|
08 May 2020 |
Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University to Develop Novel Oligonucleotide Platform for the Treatment of Genetically Driven Cancers
|
|
08 May 2020 |
Lineage Cell Therapeutics Announces Early Exercise of Option with Cancer Research UK for Immuno-Oncology Cell Therapy Program
|
|
07 May 2020 |
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors
|
|
06 May 2020 |
Avectas and ONK Therapeutics to Develop Off-the-Shelf Cancer Therapy
|
|
06 May 2020 |
Rebiotix and Ferring Announce World’s First With Positive Preliminary Pivotal Phase 3 Data for Investigational Microbiome-based Therapy RBX2660
|
|
06 May 2020 |
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors
|
